STRATA Skin Sciences a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced a fully paid exclusive and perpetual license agreement with a strategic entity for a de-identified digital image library of pigmented lesions and their related documentary information, related to STRATA’s discontinued MelaFind device. STRATA retains all intellectual property rights related to the MelaFind device and product line, including patents, design files and PMA approval to market. The strategic entity will be allowed exclusive rights to the de-identified digital images.
“We are pleased to come to agreement with this licensing partner for the de-identified images related to the MelaFind device. Rationalizing the MelaFind assets is one step in our ongoing strategic turn-around efforts following our recent financing,” said Dr. Dolev Rafaeli, chief executive officer of STRATA. “While we will look for additional licensing opportunities and continue to evaluate potential M&A opportunities, our main focus is on rebuilding our XTRAC network, expanding internationally and executing on our proven revenue strategy.”
The perpetual license agreement is subject to customary closing conditions.
Date: July 30, 2018
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: globenewswire